Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-018908
Filing Date
2024-05-13
Accepted
2024-05-13 16:31:03
Documents
48
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 445599
2 ex31-1.htm EX-31.1 11521
3 ex31-2.htm EX-31.2 11476
4 ex32-1.htm EX-32.1 6560
5 ex32-2.htm EX-32.2 6644
  Complete submission text file 0001493152-24-018908.txt   2596567

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mira-20240331.xsd EX-101.SCH 21651
7 XBRL CALCULATION FILE mira-20240331_cal.xml EX-101.CAL 29919
8 XBRL DEFINITION FILE mira-20240331_def.xml EX-101.DEF 77543
9 XBRL LABEL FILE mira-20240331_lab.xml EX-101.LAB 182542
10 XBRL PRESENTATION FILE mira-20240331_pre.xml EX-101.PRE 142072
51 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 264328
Mailing Address 324 SOUTH HYDE PARK AVENUE, SUITE 350 TAMPA FL 33606
Business Address 1200 BRICKELL AVENUE SUITE 1950 #1183 MIAMI FL 33131 813-369-5150
MIRA PHARMACEUTICALS, INC. (Filer) CIK: 0001904286 (see all company filings)

EIN.: 853354547 | State of Incorp.: FL
Type: 10-Q | Act: 34 | File No.: 001-41765 | Film No.: 24939602
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)